Vfend was initially approved in the US for the primary treatment of
acute invasive aspergillosis and salvage therapy for rare but serious infections caused by the pathogens Scedosporium apiospermum and Flusarium spp.
for the primary treatment of
acute invasive aspergillosis and salvage therapy for rare but serious fungal infections caused by the pathogens Scedosporium apiospermum and Fusarium spp.
Denning and colleagues conducted an open, noncomparative, multicenter trial to evaluate the efficacy and safety of voriconazole in the treatment of
acute invasive aspergillosis (22).
Oral, esophageal, and pharyngeal candidiasis and
acute invasive aspergillosis have responded well in clinical trials.